SCHEMBL20965473

SCHEMBL20965473

CCN1CCC2(CCN(C(=O)OC(C)(C)C)C2)C1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SCD5 Q86SK9 1/20 0.48
▸ CYP11B2 P19099 1/20 0.45
▸ RORC P51449 1/20 0.45
▸ ACACB O00763 5/20 0.44
▸ GPR183 P32249 1/20 0.42
▸ USP2 O75604 2/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ HDAC2 Q92769 2/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ CYP2D6 P10635 3/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ CYP2C9 P11712 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ TNKS O95271 1/20 0.38
▸ PARP1 P09874 1/20 0.38
▸ TNKS2 Q9H2K2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20328229 0.93 CYP3A4 (0.46) SCD5RORCUSP2CYP2D6CYP1A2
SCHEMBL20962658 0.93 SCD5 (0.46) SCD5CYP11B2RORCACACBGPR183
SCHEMBL23551919 0.93 RORC (0.48) SCD5CYP11B2RORCACACBGPR183
SCHEMBL15871707 0.93 USP2 (0.45) SCD5CYP11B2RORCACACBUSP2
SCHEMBL17946542 0.91 SCD5 (0.45) SCD5CYP11B2RORCACACBGPR183
SCHEMBL20353659 0.86 CYP2D6 (0.48) SCD5USP2SMN1; SMN2CYP2D6TSHR
SCHEMBL20382070 0.86 CYP11B2 (0.43) SCD5CYP11B2RORCACACBUSP2
SCHEMBL10264330 0.84 CYP11B2 (0.46) SCD5CYP11B2RORCACACBGPR183
SCHEMBL616762 0.84 SCD5 (0.46) SCD5CYP11B2RORCACACBGPR183
SCHEMBL21336897 0.83 RORC (0.44) SCD5CYP11B2RORCACACBGPR183

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190127373-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2019-05-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127373-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF SCD5 4793/4885CYP11B2 2621/4885RORC 874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback